Sabcomeline (BCI-224; BRL-55473; CEB-2424; SB-202026A) is a novel, potent and selective M1 receptor partial agonist that was under development for the treatment of Alzheimer's disease. It was advanced to phase III clinical trials before being discontinued due to unsatisfactory results.

纯度：≥98%

CAS：159912-58-0